Cite
Reese JT, Coleman B, Chan L, et al. Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv. 2021;doi: 10.1101/2021.04.13.21255438.
Reese, J. T., Coleman, B., Chan, L., Blau, H., Callahan, T. J., Cappelletti, L., Fontana, T., Bradwell, K. R., Harris, N. L., Casiraghi, E., Valentini, G., Karlebach, G., Deer, R., McMurry, J. A., Haendel, M. A., Chute, C. G., Pfaff, E., Moffitt, R., Spratt, H., Singh, J., Mungall, C. J., Williams, A. E., & Robinson, P. N. (2021). Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.04.13.21255438
Reese, Justin T, et al. "Cyclooxygenase inhibitor use is associated with increased COVID-19 severity." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.04.13.21255438
Reese JT, Coleman B, Chan L, Blau H, Callahan TJ, Cappelletti L, Fontana T, Bradwell KR, Harris NL, Casiraghi E, Valentini G, Karlebach G, Deer R, McMurry JA, Haendel MA, Chute CG, Pfaff E, Moffitt R, Spratt H, Singh J, Mungall CJ, Williams AE, Robinson PN. Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv. 2021 Apr 20; doi: 10.1101/2021.04.13.21255438. PMID: 33907758; PMCID: PMC8077581.
Copy
Download .nbib